NCT05005819View on ClinicalTrials.gov

Evaluation of [18F]APN-1607 as a PET Biomarker

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions

Progressive Supranuclear PalsyHealthy Volunteers

Interventions

DRUG

[18F] APN-1607

Subjects will undergo PET imaging using \[18F\]APN-1607.

Trial Locations (1)

06510

Invicro, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Invicro

OTHER